The global atrial fibrillation diagnosis market size is expected to reach USD 2.11 Billion in 2028 at a CAGR of 6.4% during the forecast period, according to the latest report by Reports and Data. Increasing global prevalence of atrial fibrillation diagnosis (AFib) due to rising incidence of cardiovascular diseases and other chronic conditions, technological advancements in atrial fibrillation diagnosis devices, and increasing product approvals from FDA for treatment of atrial fibrillation diagnosis are key factors expected to drive market revenue growth over the forecast period. In addition, rapid advancements in clinical treatment of atrial fibrillation diagnosis and availability of advanced medical devices are further expected to drive revenue growth of the market going ahead.
atrial fibrillation diagnosis is the most common type of cardiac arrhythmia with a global prevalence of nearly 2%. atrial fibrillation diagnosis is a supraventricular tachyarrhythmia caused to abnormal electrical activity that leads to uncoordinated atrial activation and uncoordinated atrial contraction. atrial fibrillation diagnosis results in a turbulent and abnormal blood flow through chambers of the heart, which in turn, results in decreased effectiveness of the heart to pump blood. Uncoordinated atrial contraction decreases the cardiac output by nearly 20% and this is further exacerbated in mitral stenosis, hypertension, and impaired diastolic ventricular filling, among other conditions. atrial fibrillation diagnosis can be asymptomatic or symptomatic, with symptoms including chest pain, dizziness, nausea, fast heart rate, and generalized fatigue. Advanced age, high blood pressure, congenital heart disease, and underlying heart and lung disorders are some major risk factors for atrial fibrillation diagnosis. Over the recent years, extensive research & development projects is resulting in development of advanced clinical treatment of atrial fibrillation diagnosis and risk modifying strategies to minimize the risk of stroke and other cardiac complications in patients with AFib.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1440
Some Key Highlights from the Report:
- EP ablation catheters segment is expected to account for a significantly large revenue share in the global market over the forecast period attributable to rising preference for catheter ablation for diagnosis and treatment of atrial fibrillation diagnosis. atrial fibrillation diagnosis is considered as the most promising indication for cardiac ablation owing to its increasing unresponsiveness to existing treatment and growing prevalence across the globe.
- Hospitals segment is expected to register robust revenue CAGR over the forecast period owing to increasing patient admissions in hospitals, rising number of catheter ablation procedures performed in hospital settings, availability of skilled professionals and state-of-the-art healthcare infrastructure, advanced post-operative facilities, and growing preference for minimally invasive surgical procedures.
- North America is expected to account for largest revenue share between 2021 and 2028 attributable to increasing number of atrial fibrillation diagnosis treatment procedures performed due to rising incidence of cardiovascular diseases, growing investment to advance clinical treatment of atrial fibrillation diagnosis, availability of robust healthcare infrastructure and facilities, implementation of favorable reimbursement policies, and increasing FDA approvals for medical devices and treatment.
- In September 2021, Match Health Academy, which is an online learning platform, announced the launch of three online video courses offered by experts to educate patients and their families understand atrial fibrillation diagnosis and help them in managing it. Match Health Academy offers online learning with self-paced courses that help patients and their families improve their knowledge and understanding of health conditions and available treatment approaches.
Top Players in the Global atrial fibrillation diagnosis Market:
Abbott Laboratories, Atricure Inc., Johnson & Johnson, Microport Scientific Corporation, Boston Scientific Corporation, Biosense Webster, Inc., St. Jude Medical, Inc., Siemens AG, Medtronic Plc, Koninklijke Philips N.V., Cardiofocus, Inc., Biotitic Se & Co. Kg, Inc., Carima, Inc., Ncontact, Inc., and Agricore, Inc.
To know more about the report @ https://www.reportsanddata.com/report-detail/atrial-fibrillation-market
atrial fibrillation diagnosis Market Segmentation:
Type Outlook (Revenue, USD Billion; 2018-2028)
- EP Ablation Catheters
- Cardiac Monitors
- EP Diagnostic Catheter
- Mapping and Recording Systems
- Access Devices
- Intracardiac Echocardiography
End-Use Outlook (Revenue, USD Billion; 2018-2028)
- Hospitals
- Cardiac Centers
- Ambulatory Care Centers
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1440
Read More Reports:
Eyedrops for Cataract Market @ https://www.reportsanddata.com/report-detail/eyedrops-for-cataract-market
High Potency Active Pharmaceutical Ingredients (HPAPI) Market @ https://www.reportsanddata.com/report-detail/high-potency-active-pharmaceutical-ingredients-hpapi-market
Infant Radiant Warmer Market @ https://www.reportsanddata.com/report-detail/infant-radiant-warmer-market
Cryogenic Vials Market @ https://www.reportsanddata.com/report-detail/cryogenic-vials-market-research
Alcohol Dehydrogenase Market @ https://www.reportsanddata.com/report-detail/alcohol-dehydrogenase-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
However, lack of well-trained physicians and the high cost of treatments are hampering the atrial fibrillation market growth.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1541The report has provided a detailed profile of some of the leading players in the global atrial fibrillation market such as Abbott Laboratories, Biosense Webster, Inc., Medtronic Plc, MicroPort Scientific Corporation, Boston Scientific Corporation, Biotronik SE & Co. KG, CardioFocus, Inc., AtriCure Inc., Koninklijke Philips N.V., and Osypka AG.
The market is also estimated to reach US$ 10,925.1 million revenue by the end of 2026.On the basis of product type, the EP ablation catheters are expected to emerge as the most preferred product in the global atrial fibrillation market.
On the basis of end-user, the market is segmented into electrophysiology labs, hospitals, and ambulatory surgical center.
A maximum number of catheter ablation are performed in Germany.Buy Atrial Fibrillation Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=1541=SRise in the Use of Less Invasive and Advanced Treatment for Atrial FibrillationMajor hospitals and medical centers are using a less invasive procedure known as catheter ablation for treating atrial fibrillation.
It also has facilitated quick recovery than the surgery.
A recent study by the researchers at the Klinikum Coburg and the University of Utah Health also showed that radiofrequency catheter ablation lowered mortality rates in patients suffering from atrial fibrillation.
